<SEC-DOCUMENT>0001062822-21-000009.txt : 20210310
<SEC-HEADER>0001062822-21-000009.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310161222
ACCESSION NUMBER:		0001062822-21-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210310
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		21729809

	BUSINESS ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		8800 TECHNOLOGY FOREST PLACE
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20210310.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5,d:339cc295a86c4da399c0508a621b56f5--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20210310</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV80L2ZyYWc6YzFhOTA2ZTViOTZlNDllYmJiZmEyZTNiYTkwZGNhOGEvdGFibGU6ZWRmNmNkYzdiNDUxNGFkMDg5NTM5OTJmYmU1ZjZjNjEvdGFibGVyYW5nZTplZGY2Y2RjN2I0NTE0YWQwODk1Mzk5MmZiZTVmNmM2MV8wLTEtMS0xLTA_523a4906-c1ec-4169-bb80-ba2e1f40c7f5">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV80L2ZyYWc6YzFhOTA2ZTViOTZlNDllYmJiZmEyZTNiYTkwZGNhOGEvdGFibGU6ZWRmNmNkYzdiNDUxNGFkMDg5NTM5OTJmYmU1ZjZjNjEvdGFibGVyYW5nZTplZGY2Y2RjN2I0NTE0YWQwODk1Mzk5MmZiZTVmNmM2MV8xLTEtMS0xLTA_118cf7c3-aa85-4357-88d8-489c45eac545">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20210310.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-10</xbrli:startDate><xbrli:endDate>2021-03-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i339cc295a86c4da399c0508a621b56f5_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg3_e1cb2dec-89c0-4205-b06f-bfc574842827">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8yNjY_95c9fb28-31f8-4142-b02e-6eeef5cbae30">March 10, 2021</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg1_8c6dc1a1-0aaa-4337-a114-df7ccf12efed">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTAtMS0xLTA_1d7913c2-09e7-4229-951a-4565bb9dae2b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTEtMS0xLTA_1d9ef27b-5caa-4af6-bd0e-645884dba273">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTItMS0xLTA_2e8158c8-1d04-4388-a582-2d0ea980c390">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkx_1236d011-e94c-4e1a-9243-1bd950dd2911">8800 Technology Forest Place</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgw_753345b4-b84a-4564-879e-8d815e916999">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgx_69d26dc9-95d0-4182-a48d-cadbefe9e0a1">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV80MDk_5306ee45-a392-4dad-97a3-a3bfab634f93">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV80Njg_d036eab9-8793-4614-84e9-2704a644475d">281</ix:nonNumeric>) <ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg4_0c4fc21b-4eea-431f-a985-d814beba87b9">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTAtMS0xLTA_9d1c53bb-6c32-4101-80da-3f7c34201e90">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTEtMS0xLTA_d133cd69-2389-4094-b771-2fc3d47765aa">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTItMS0xLTA_7c1436da-5ab6-40f9-93a6-f07a519dd7f3">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgy_254ba5d4-26ba-40b6-a1bc-66f6bc4e4d48">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkz_d7b5fb13-0049-4d84-a2b5-adb32297eb21">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkw_4b794f38-1c40-4f70-bc65-48ab5e9279fb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg2_950b72a9-bdd0-4603-a09e-cd1ff21c1afc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg0_7ed236ad-36a3-44cc-9784-fc0b5e66bd5a">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i339cc295a86c4da399c0508a621b56f5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operation and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 10, 2021, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release to report our financial results for the quarter ended December 31, 2020.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i339cc295a86c4da399c0508a621b56f5_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-10x.htm">Press Release of Lexicon Pharmaceuticals, Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-10x.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-10x.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings03-10x.htm">March 10, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i339cc295a86c4da399c0508a621b56f5_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:52.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   March 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseearnings03-10x.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i280263d486884cb697054f5b69b01427_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Conference Call and Webcast at 5&#58;00 pm Eastern Time</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">The Woodlands, Texas, March 10, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> - Lexicon Pharmaceuticals, Inc. (Nasdaq&#58; LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;During 2020, we substantially strengthened our balance sheet by eliminating 95% of our debt and returned to our roots by focusing on the advancement of our research and development pipeline,&#8221; said Lonnel Coats, Lexicon&#8217;s president and chief executive officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;We took key steps to advance our pipeline by initiating two proof-of-concept Phase 2 studies of LX9211 in diabetic peripheral neuropathic pain and post-herpetic neuralgia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We efficiently closed out the sotagliflozin Phase 3 clinical program and, based on positive data from two of those Phase 3 studies, SCORED and SOLOIST, we believe that sotagliflozin has the potential to become an important new treatment option for heart failure patients with type 2 diabetes. We will be working expeditiously to file an NDA for sotagliflozin in heart failure in the second half of this year.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">With minimal debt and cash sufficient to fund our planned operations for two years, we entered 2021 in a solid financial position to execute on these objectives.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Fourth Quarter Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LX9211</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Patient enrollment continued in RELIEF-DPN-1, a Phase 2 clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Enrollment is expected to total approximately 300 patients at approximately 30 clinical sites.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Patient enrollment commenced in RELIEF-PHN 1, a Phase 2 clinical study of LX9211 for the treatment of post-herpetic neuralgia. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Enrollment is expected to total approximately 74 patients at approximately 30 clinical sites.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lexicon received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sotagliflozin</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Data from both studies were presented at the Late-Breaking Science Session of the American Heart Association Scientific Sessions 2020 and simultaneously published in two separate articles in The New England Journal of Medicine.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Corporate Activities</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lexicon raised $70 million in net proceeds from common stock sales.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">2021 Anticipated Milestones and Events</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">NDA filing for sotagliflozin in heart failure.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Active efforts to secure strategic alliance for sotagliflozin in heart failure.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Phase 2 study results from </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">RELIEF-DPN-1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">for LX9211 in diabetic peripheral neuropathic pain.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Phase 2 study results from RELIEF-PHN-1 for LX9211 in post-herpetic neuralgia.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additional publications for sotagliflozin and LX9211.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Fourth Quarter and Full-Year 2020 Financial Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2020 compared to the fourth quarter and full year of 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Revenues for the fourth quarter of 2020 decreased to $0.2 million from $8.7 million for the corresponding period in 2019, primarily due to the elimination of product revenues as a result of the sale of XERMELO during the third quarter of 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full-year 2020 revenues decreased to $24.0 million from $322.1 million in 2019.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full-year 2019 revenues included collaborative revenues of $289.2 million, primarily from the termination of the alliance with Sanofi and recognition of the remaining amounts for performance obligations from the initial agreement with Sanofi.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Due to a reduction in external clinical development cost estimates primarily related to sotagliflozin, research and development expenses for the fourth quarter of 2020 decreased to $1.0 million from $40.6 million for the corresponding period in 2019.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full-year R&#38;D expenses for 2020 increased to $153.6 million from $91.9 million in 2019, primarily due to increases in external clinical development costs related to sotagliflozin subsequent to the termination of the alliance with Sanofi in September 2019.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Selling, General and Administrative (SG&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Selling, general and administrative expenses for the fourth quarter of 2020 decreased to $6.4 million from $14.6 million for the corresponding period in 2019, primarily due to lower salaries and benefits as a result of reductions in personnel and elimination of marketing expenses following the sale of XERMELO in the third quarter of 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Full-year SG&#38;A expenses for 2020 decreased to $47.2 million from $56.8 million, primarily due to lower salaries and benefits and marketing costs. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Gain on Sale of XERMELO&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">A gain of $132.6 million was recognized during 2020 from the sale of XERMELO and related assets to TerSera Therapeutics LLC in September 2020.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Net Income (Loss)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> Net loss for the fourth quarter of 2020 was $5.5 million, or $0.04 per share, as compared to a net loss of $51.1 million, or $0.48 per share, in the corresponding period in 2019. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For the three months ended December 31, 2020 and 2019, net loss included non-cash, stock-based compensation expense of $2.7 million and $3.5 million, respectively. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Net loss for the year ended December 31, 2020 was $58.6 million, or $0.53 per share, as compared to a net income of $130.1 million, or $1.16 per diluted share, in 201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9. For the years ended December 31, 2020 and 2019, net loss included non-cash, stock-based compensation expense of $13.3 million and $14.2 million, respectively.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cash and Investments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> As of December 31, 2020, Lexicon had $152.3 million in cash and investments, as compared to $271.7 million as of December 31, 2019.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lexicon management will hold a live conference call and webcast today at 5&#58;00 pm ET &#47; 4&#58;00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-645-5785 (U.S.&#47;Canada) or 970-300-1531 (international). The conference ID for all callers is 3793713. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at www.lexpharma.com&#47;investors. An archived version of the webcast will be available on the website for 14 days. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">About Lexicon Pharmaceuticals</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For additional information, please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">www.lexpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i280263d486884cb697054f5b69b01427_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.740%"><tr><td style="width:1.0%"></td><td style="width:39.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selected Financial Data</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,568&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,404&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,331&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,231&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,727&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,995&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,073&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;asset amortization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $1,223, $1,727, $6,376 and $7,096, respectively</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,606&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,621&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,924&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 7pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $1,457, $1,752, $6,898 and $7,122, respectively</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,564&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,230&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on intangible asset</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,638&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,424&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,944&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,380&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,628&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on sale of XERMELO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,585&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,217)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,800)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,445&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,191)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,544)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,676)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) before income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,495)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,138)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,119&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,014&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,495)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,138)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,133&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, basic</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,359&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,218&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share, diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,359&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,272&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,747&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;As of </font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash and investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,275&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,659&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Property and equipment, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,716&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,788&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,715&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Current and long-term debt</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,646&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,183&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Accumulated deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400,018)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,341,444)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total stockholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,371&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i280263d486884cb697054f5b69b01427_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Chas Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Executive Director, Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">(281) 863-3421</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">cschultz&#64;lexpharma.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20210310.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20210310" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20210310">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210310_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210310_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210310_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20210310_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lxrx-20210310_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20210310.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lxrx-20210310_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20210310.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended" id="i4055844a7b48470aaee8b1f98d59fdf7_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lxrx-20210310_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_9ec0d6ba-7932-4dd5-8a29-b14426117c60_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d151a310-f699-4da9-b19d-9c05e9c4a7da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f7adf352-bf7a-4486-ac89-15f5750110e6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_243fc6e2-003c-4b1e-badd-1ce2b8004141_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_7e495997-cbe6-4b54-a777-cce0e81cd98e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_40966968-54a5-4a30-8b33-07508310c18b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_899c31d6-563a-4d1e-88e9-6cb9269212c7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ff04cab8-f917-4789-913e-80c152f134af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b1506d9e-a8b4-4860-a0ae-a0d8cb3d4eeb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_bff99b9f-60ef-4cd4-a468-27af1dfb4398_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c4e0270d-3313-4bc8-ac2f-60366de5fa91_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1660a1a6-a644-4d75-a88f-2a98b2e50818_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5fc2aa7c-3402-4652-953f-b48aa2f08f02_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_12e05064-1eab-4ab3-abe3-8f8521b6de8d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_e4c1bc3e-bc63-459d-8aa2-8423f3c2b4b4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_eebc4641-3bef-42ef-98de-b98b12ec5dff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8dedb6df-b986-465d-8061-937656c567a5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4a6f68ff-ab81-4d02-a909-5fbf7b58b910_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f3aaa576-de8a-402e-b15c-77140f6cdba9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4e4891c3-93f2-4b32-a1ac-21acd2b8287e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_666f3b38-df2b-4d29-aede-a920465ec66f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6f24da38-c3b9-44e6-b48f-86871722b068_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lxrx-20210310_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9749b6e2-b93e-4872-a753-bfd021e59468,g:b6f14672-3e84-406e-9191-6e1be4125ab5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20210310.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_05a94838-e32e-4d4a-870e-92d9bba88e60" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_DocumentType_05a94838-e32e-4d4a-870e-92d9bba88e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_79adf11b-ae12-4d34-89c7-1c17394eb6f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_DocumentPeriodEndDate_79adf11b-ae12-4d34-89c7-1c17394eb6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1f7fde7b-63b7-4844-8ef2-89d3fb8c347e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityRegistrantName_1f7fde7b-63b7-4844-8ef2-89d3fb8c347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5493e4f1-8a9f-48b6-93ca-13da43ff382a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5493e4f1-8a9f-48b6-93ca-13da43ff382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9eb6b079-46cd-44cc-aedc-e1c48e92324b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityFileNumber_9eb6b079-46cd-44cc-aedc-e1c48e92324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82c786ea-fc24-4c90-b069-c39405b1485e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityTaxIdentificationNumber_82c786ea-fc24-4c90-b069-c39405b1485e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f6f364ca-2d13-4132-9ebe-6aaf6fe13e42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityAddressAddressLine1_f6f364ca-2d13-4132-9ebe-6aaf6fe13e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1e58097d-59ca-46c8-a154-147b4cac6767" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityAddressCityOrTown_1e58097d-59ca-46c8-a154-147b4cac6767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_52316b9d-a609-4590-83f2-6914b9fe2f5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityAddressStateOrProvince_52316b9d-a609-4590-83f2-6914b9fe2f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f8377e93-2ef9-44f6-bcf8-19299ac7f746" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityAddressPostalZipCode_f8377e93-2ef9-44f6-bcf8-19299ac7f746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_505acc0c-3416-47d0-9f0b-e104ea0c6aef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_CityAreaCode_505acc0c-3416-47d0-9f0b-e104ea0c6aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fca61ed7-c637-4366-b2ae-1cba55513cf4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_LocalPhoneNumber_fca61ed7-c637-4366-b2ae-1cba55513cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6b2e5457-21a6-4551-b378-e1e8df2a73ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_Security12bTitle_6b2e5457-21a6-4551-b378-e1e8df2a73ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4472de10-c252-433f-b50c-c027bb4ce175" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_TradingSymbol_4472de10-c252-433f-b50c-c027bb4ce175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3d15fdf3-c579-4a7f-b40c-c7bb9b0a9bfb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_SecurityExchangeName_3d15fdf3-c579-4a7f-b40c-c7bb9b0a9bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cd9352b9-809e-4621-96f3-b91383b0f173" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_WrittenCommunications_cd9352b9-809e-4621-96f3-b91383b0f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_f5b800e5-3bcb-480e-ad0c-023a3bfb96ca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_SolicitingMaterial_f5b800e5-3bcb-480e-ad0c-023a3bfb96ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6eba5d13-b10b-4078-a217-a6e292ecaf55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_PreCommencementTenderOffer_6eba5d13-b10b-4078-a217-a6e292ecaf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ab37ab0-8517-4e3e-a3ff-ef17a78bd926" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ab37ab0-8517-4e3e-a3ff-ef17a78bd926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2a917a12-260a-4a41-a28d-a749d78e2c42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityEmergingGrowthCompany_2a917a12-260a-4a41-a28d-a749d78e2c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_359e7d10-f967-40de-ab5a-4eedf2eedd5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_EntityCentralIndexKey_359e7d10-f967-40de-ab5a-4eedf2eedd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aedee064-6c8e-4a84-9bc8-9841d680ce8c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b8600310-f8f9-4f9f-b2d8-d97a40ab6afb" xlink:to="loc_dei_AmendmentFlag_aedee064-6c8e-4a84-9bc8-9841d680ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>lxrx-20210310_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20210310.xsd" xlink:type="simple"/>
    <context id="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-03-10</startDate>
            <endDate>2021-03-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV80L2ZyYWc6YzFhOTA2ZTViOTZlNDllYmJiZmEyZTNiYTkwZGNhOGEvdGFibGU6ZWRmNmNkYzdiNDUxNGFkMDg5NTM5OTJmYmU1ZjZjNjEvdGFibGVyYW5nZTplZGY2Y2RjN2I0NTE0YWQwODk1Mzk5MmZiZTVmNmM2MV8wLTEtMS0xLTA_523a4906-c1ec-4169-bb80-ba2e1f40c7f5">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV80L2ZyYWc6YzFhOTA2ZTViOTZlNDllYmJiZmEyZTNiYTkwZGNhOGEvdGFibGU6ZWRmNmNkYzdiNDUxNGFkMDg5NTM5OTJmYmU1ZjZjNjEvdGFibGVyYW5nZTplZGY2Y2RjN2I0NTE0YWQwODk1Mzk5MmZiZTVmNmM2MV8xLTEtMS0xLTA_118cf7c3-aa85-4357-88d8-489c45eac545">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg3_e1cb2dec-89c0-4205-b06f-bfc574842827">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8yNjY_95c9fb28-31f8-4142-b02e-6eeef5cbae30">2021-03-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg1_8c6dc1a1-0aaa-4337-a114-df7ccf12efed">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTAtMS0xLTA_1d7913c2-09e7-4229-951a-4565bb9dae2b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTEtMS0xLTA_1d9ef27b-5caa-4af6-bd0e-645884dba273">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6MzYyZjg1OTQ2ZThlNDQ3NTliYzM5NDI4ZTcyOWIwN2IvdGFibGVyYW5nZTozNjJmODU5NDZlOGU0NDc1OWJjMzk0MjhlNzI5YjA3Yl8wLTItMS0xLTA_2e8158c8-1d04-4388-a582-2d0ea980c390">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkx_1236d011-e94c-4e1a-9243-1bd950dd2911">8800 Technology Forest Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgw_753345b4-b84a-4564-879e-8d815e916999">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgx_69d26dc9-95d0-4182-a48d-cadbefe9e0a1">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV80MDk_5306ee45-a392-4dad-97a3-a3bfab634f93">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV80Njg_d036eab9-8793-4614-84e9-2704a644475d">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg4_0c4fc21b-4eea-431f-a985-d814beba87b9">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTAtMS0xLTA_9d1c53bb-6c32-4101-80da-3f7c34201e90">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTEtMS0xLTA_d133cd69-2389-4094-b771-2fc3d47765aa">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGFibGU6YzAxNGJkNzFhMjAxNDVhOTkyNTRjOGE3NmNlZTUyYjQvdGFibGVyYW5nZTpjMDE0YmQ3MWEyMDE0NWE5OTI1NGM4YTc2Y2VlNTJiNF8xLTItMS0xLTA_7c1436da-5ab6-40f9-93a6-f07a519dd7f3">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjgy_254ba5d4-26ba-40b6-a1bc-66f6bc4e4d48">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkz_d7b5fb13-0049-4d84-a2b5-adb32297eb21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjkw_4b794f38-1c40-4f70-bc65-48ab5e9279fb">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg2_950b72a9-bdd0-4603-a09e-cd1ff21c1afc">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzOWNjMjk1YTg2YzRkYTM5OWMwNTA4YTYyMWI1NmY1L3NlYzozMzljYzI5NWE4NmM0ZGEzOTljMDUwOGE2MjFiNTZmNV8xL2ZyYWc6YWNlZjdmNDA3ZjE1NDAzNWE2NTQxZDlhNWU2Njk5ZWEvdGV4dHJlZ2lvbjphY2VmN2Y0MDdmMTU0MDM1YTY1NDFkOWE1ZTY2OTllYV8xNjg0_7ed236ad-36a3-44cc-9784-fc0b5e66bd5a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140446819027544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 10,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 Technology Forest Place<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M*TUTDH#WS*P.7\Y(R@QY93+GY&?_PO?1]%5;!,5M?&Y8)-2*S-Z2A9:UC+C
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M%     @ BH%J4H.II0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ BH%J4JK$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "*@6I299!YDAD!  #/ P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C
M3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=
M(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B
M63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.Q
MD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[
MV?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D
M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( (J!
M:E('04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ BH%J4DU%%@;M    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ BH%J4IE<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "*@6I2=&"T@34$   ]$   &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ BH%J4H.II0/4 0
M,@8   T              ( !=PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "*@6I2EXJ[',     3 @  "P              @ %V#@  7W)E;',O+G)E
M;'-02P$"% ,4    " "*@6I2JL0B%C,!   B @  #P              @ %?
M#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ BH%J4B0>FZ*M    ^ $
M !H              ( !OQ   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ BH%J4F60>9(9 0  SP,  !,              ( !I!$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  [A(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20210310.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20210310.htm">lxrx-20210310.htm</File>
    <File>lxrx-20210310.xsd</File>
    <File>lxrx-20210310_cal.xml</File>
    <File>lxrx-20210310_def.xml</File>
    <File>lxrx-20210310_lab.xml</File>
    <File>lxrx-20210310_pre.xml</File>
    <File>pressreleaseearnings03-10x.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20210310.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20210310_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20210310_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20210310.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20210310_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20210310_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20210310.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20210310",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210310.htm",
      "contextRef": "ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20210310.htm",
      "contextRef": "ibd2882c431ee43aea09f103ff5f936d8_D20210310-20210310",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001062822-21-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-21-000009-xbrl.zip
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M:/7Z9^ON^\GY:PV[HWTQ^ %02P,$%     @ BH%J4@5[=Q2" 0  R (  !4
M  !L>')X+3(P,C$P,S$P7V-A;"YX;6R=DDUOVS ,AN_Y%9IWG2S+=IS(B%-@
M&08,R"[IBO8JVW0L1)8,2:W=?S]+;39T'QBPBP22#_F2E'8W\R#1$Q@KM*HB
M&B<1 M7H5JAS%=U]^XRWT<U^M=J]P_CAX^F(/NGF<0#ET,$ =]"B2;@>W;=@
M+Z@S>D#WVES$$\=X'Y(.>GPVXMP[E"8I_35J2K;)65U BFN6 <ZWFQ3SS3K#
M==<N/*Q97FP_G,NZZ&A>+,$,MCG.DP(PHXSB F@-.4W7O%Z'HE*H2^F/FEM
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M?=@Y:/5AEH]IX(GQ[N5=*^1=3>E1!0YV,5AA<$UVLU8X?Z9W^=B\FC662,A
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MN^@[)D[.FW7KJO^5JVU1G8S0&JP@'#II9%+$AV0(L]Q:%W324@U-R0,/^K7
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M=79Y<79>.?W^M0+.-!V9_Y'I0>,QS'D!(R]]K.P[2_D%!=2T&Z;8WN>S,57
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M>"TR,#(Q,#,Q,%]D968N>&UL4$L! A0#%     @ BH%J4I,[7>D["@  HET
M !4              ( !K1H  &QX<G@M,C R,3 S,3!?;&%B+GAM;%!+ 0(4
M Q0    ( (J!:E)"_3!LJ08  &@Q   5              "  1LE  !L>')X
M+3(P,C$P,S$P7W!R92YX;6Q02P$"% ,4    " "*@6I2'?2 ZR@<  #2;P$
M'@              @ 'W*P  <')E<W-R96QE87-E96%R;FEN9W,P,RTQ,'@N
9:'1M4$L%!@     '  < U@$  %M(      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
